146 related articles for article (PubMed ID: 12754444)
1. [Contribution of linezolid to the treatment of nosocomial pneumonia].
Gouin F
Presse Med; 2003 Apr; 32(13 Pt 2):S13-6. PubMed ID: 12754444
[TBL] [Abstract][Full Text] [Related]
2. Linezolid - the first oxazolidinone in the treatment of nosocomial MRSA pneumonia.
Burkhardt O; Pletz MW; Mertgen CP; Welte T
Recent Pat Antiinfect Drug Discov; 2007 Jun; 2(2):123-30. PubMed ID: 18221168
[TBL] [Abstract][Full Text] [Related]
3. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
Stein GE; Wells EM
Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
[TBL] [Abstract][Full Text] [Related]
4. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.
Wang Y; Zou Y; Xie J; Wang T; Zheng X; He H; Dong W; Xing J; Dong Y
Eur J Clin Pharmacol; 2015 Jan; 71(1):107-15. PubMed ID: 25355172
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.
Maclayton DO; Hall RG
Ann Pharmacother; 2007 Feb; 41(2):235-44. PubMed ID: 17299012
[TBL] [Abstract][Full Text] [Related]
6. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials.
Walkey AJ; O'Donnell MR; Wiener RS
Chest; 2011 May; 139(5):1148-1155. PubMed ID: 20864609
[TBL] [Abstract][Full Text] [Related]
7. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.
Jiang H; Tang RN; Wang J
Eur J Clin Microbiol Infect Dis; 2013 Sep; 32(9):1121-8. PubMed ID: 23568605
[TBL] [Abstract][Full Text] [Related]
8. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Estes L; Orenstem R
Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
[No Abstract] [Full Text] [Related]
10. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
Alaniz C; Pogue JM
Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
[TBL] [Abstract][Full Text] [Related]
12. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.
Pletz MW; Burkhardt O; Welte T
Eur J Med Res; 2010 Nov; 15(12):507-13. PubMed ID: 21163725
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.
Machado AR; Arns Cda C; Follador W; Guerra A
Braz J Infect Dis; 2005 Jun; 9(3):191-200. PubMed ID: 16224625
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Daniel Mullins C; Kuznik A; Shaya FT; Obeidat NA; Levine AR; Liu LZ; Wong W
Clin Ther; 2006 Aug; 28(8):1184-1198. PubMed ID: 16982296
[TBL] [Abstract][Full Text] [Related]
15. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses.
Powers JH; Ross DB; Lin D; Soreth J
Chest; 2004 Jul; 126(1):314-5; author reply 315-6. PubMed ID: 15249482
[No Abstract] [Full Text] [Related]
16. Pneumonia caused by methicillin-resistant Staphylococcus aureus.
Rubinstein E; Kollef MH; Nathwani D
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S378-85. PubMed ID: 18462093
[TBL] [Abstract][Full Text] [Related]
17. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
Chavanet P
Med Mal Infect; 2013 Dec; 43(11-12):451-5. PubMed ID: 24238896
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Lyles A
Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
20. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Puzniak LA; Morrow LE; Huang DB; Barreto JN
Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
